In the field of diagnosing Thrombi diseases, it is now a well established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own GPIIb/IIIa imaging agents.
This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F/68Ga\]GP1 PET imaging. \[18F/68Ga\]GP1 is a small molcule-based tracer that offers stronger binding affinity to GPIIb/IIIa. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F/68Ga\]GP1 PET imaging in human subjects.
Study Type
OBSERVATIONAL
Enrollment
500
Each subject receive a single intravenous injection of 18F/68Ga-GP1, and undergo PET/ CT or MRI imaging within the specificed time.
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China
RECRUITINGThe Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
RECRUITINGTianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
RECRUITINGStandardized uptake value (SUV)
Standardized uptake value (SUV) of 18F/68Ga-GP1 for each target lesion of subject or suspected thrombi.
Time frame: 30 days
Diagnostic efficacy
The sensitivity, specificity and accuracy of GPIIb/IIIa PET/CT were calculated.
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.